BN Business News
Bedrijf toevoegen →
Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.

Bedrijven · 9-4-20211 min lezen

Lavipharm Laboratories, Inc., et al.; Withdrawal of Approval of Five Abbreviated New Drug Applications

Lokale automatische vertaling · Oorspronkelijke brontaal

Samenvatting

The Food and Drug Administration (FDA) is withdrawing approval of five abbreviated new drug applications (ANDAs) from multiple holders of those ANDAs. The basis for the withdrawal is that these ANDA holders have repeatedly failed to file required annual reports for those ANDAs and have failed to satisfy the requirement to have an approved risk evaluation and mitigation strategy (REMS).

Oorspronkelijke brontaal: Federal Register — Food and Drug AdministrationOrigineel bericht openen →